Latest News

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

November 4th 2024

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

Rademikibart Differentiates From Dupilumab With Optimized IL-4Rα Inhibition and Enhanced Binding Stability
Rademikibart Differentiates From Dupilumab With Optimized IL-4Rα Inhibition and Enhanced Binding Stability

November 1st 2024

Effectiveness of Dupilumab on Special Sites in Atopic Dermatitis
Effectiveness of Dupilumab on Special Sites in Atopic Dermatitis

November 1st 2024

Alexander Egeberg, MD, PhD, Shares Key Findings on Chronic Hand Eczema and Atopic Dermatitis
Alexander Egeberg, MD, PhD, Shares Key Findings on Chronic Hand Eczema and Atopic Dermatitis

October 31st 2024

Uncovering Systemic Corticosteroid Use and Updates on Long-Term Management Benefits of Upadacitinib in AD
Uncovering Systemic Corticosteroid Use and Updates on Long-Term Management Benefits of Upadacitinib in AD

October 30th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.